Literature DB >> 29159779

Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.

Michiro Sasaki1, Mitsuhiro Tozaki2, Kazunori Kubota3, Wakana Murakami4, Daisuke Yotsumoto5, Yasuaki Sagara5, Yasuyo Ohi6, Shunichi Oosako7, Yoshiaki Sagara2.   

Abstract

PURPOSE: To compare standardized uptake value (SUV) and apparent diffusion coefficient (ADC) values acquired using a PET/MRI scanner in breast cancer patients.
MATERIALS AND METHODS: Whole-body PET/MRI and breast PET/MRI were performed in 108 consecutive patients. Ninety-four patients who had a total of 100 breast cancers were analyzed. SUVmax and ADCmean acquired using breast PET/MRI were compared with pathologic prognostic factors.
RESULTS: All the lesions were visually detectable using PET and diffusion-weighted imaging (DWI) on breast PET/MRI; however, lesions were visually undetectable on whole-body DWI in 13 patients (13%) or on whole-body PET in 7 patients (7%). An analysis of ADCmean and SUVmax demonstrated a statistically significant correlation between whole-body imaging and breast imaging (rho = 0.613, p < 0.001 and rho = 0.928, p < 0.001, respectively). In a univariate analysis, SUVmax was significantly correlated with HER2 status (p < 0.001), Ki-67 (p = 0.014), tumor size (p = 0.0177), and nuclear grade (p = 0.0448). In multiple regression analysis, only tumor size (p = 0.00701) was shown to independently influence SUVmax.
CONCLUSION: Prone breast imaging was more sensitive than whole-body PET/MRI for detection of breast cancers. Both SUVmax and ADCmean showed limited correlation with pathologic prognostic factors.

Entities:  

Keywords:  Apparent diffusion coefficient; Breast carcinoma; Diffusion-weighted imaging; PET/MRI; Standardized uptake value

Mesh:

Substances:

Year:  2017        PMID: 29159779     DOI: 10.1007/s11604-017-0707-y

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  31 in total

1.  Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.

Authors:  Ivan Jambor; Anna Kuisma; Susan Ramadan; Riikka Huovinen; Minna Sandell; Sami Kajander; Jukka Kemppainen; Esa Kauppila; Joakim Auren; Harri Merisaari; Jani Saunavaara; Tommi Noponen; Heikki Minn; Hannu J Aronen; Marko Seppänen
Journal:  Acta Oncol       Date:  2015-04-02       Impact factor: 4.089

Review 2.  PET/MRI system design.

Authors:  Gaspar Delso; Sibylle Ziegler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

3.  Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value.

Authors:  Savannah C Partridge; Wendy B DeMartini; Brenda F Kurland; Peter R Eby; Steven W White; Constance D Lehman
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

4.  MR-compatibility assessment of the first preclinical PET-MRI insert equipped with digital silicon photomultipliers.

Authors:  J Wehner; B Weissler; P M Dueppenbecker; P Gebhardt; B Goldschmidt; D Schug; F Kiessling; V Schulz
Journal:  Phys Med Biol       Date:  2015-02-16       Impact factor: 3.609

5.  Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology.

Authors:  Axel Martinez-Möller; Matthias Eiber; Stephan G Nekolla; Michael Souvatzoglou; Alexander Drzezga; Sibylle Ziegler; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer
Journal:  J Nucl Med       Date:  2012-08-09       Impact factor: 10.057

6.  Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.

Authors:  Leonardo Pace; Emanuele Nicolai; Angelo Luongo; Marco Aiello; Onofrio A Catalano; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Radiol       Date:  2013-11-23       Impact factor: 3.528

7.  Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.

Authors:  Onofrio Antonio Catalano; Dania Daye; Alberto Signore; Carlo Iannace; Mark Vangel; Angelo Luongo; Marco Catalano; Mazzeo Filomena; Luigi Mansi; Andrea Soricelli; Marco Salvatore; Niccolo Fuin; Ciprian Catana; Umar Mahmood; Bruce Robert Rosen
Journal:  Int J Oncol       Date:  2017-05-19       Impact factor: 5.650

8.  Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study.

Authors:  Tomoyuki Fujioka; Kazunori Kubota; Akira Toriihara; Youichi Machida; Kaori Okazawa; Tsuyoshi Nakagawa; Yukihisa Saida; Ukihide Tateishi
Journal:  World J Radiol       Date:  2016-08-28

9.  Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner.

Authors:  Gaspar Delso; Sebastian Fürst; Björn Jakoby; Ralf Ladebeck; Carl Ganter; Stephan G Nekolla; Markus Schwaiger; Sibylle I Ziegler
Journal:  J Nucl Med       Date:  2011-11-11       Impact factor: 10.057

10.  Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.

Authors:  Belgin Karan; Aysin Pourbagher; Nese Torun
Journal:  J Magn Reson Imaging       Date:  2015-12-10       Impact factor: 4.813

View more
  2 in total

1.  Does integrated shimming improve lesion detection in whole-body diffusion-weighted examinations of patients with breast cancer?

Authors:  Michiro Sasaki; Mitsuhiro Tozaki; Katsuya Maruyama; Thomas Benkert; Wakana Murakami; Daisuke Yotsumoto; Shunichi Oosako; Yoshiaki Sagara
Journal:  Jpn J Radiol       Date:  2018-09-27       Impact factor: 2.374

2.  Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Transl Oncol       Date:  2018-12-03       Impact factor: 4.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.